U.K. Coverage Rejection Of Alimta In NSCLC Increases Concerns About Access To Cancer Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K.’s NICE has rejected reimbursement under the National Health Service for Lilly’s Alimta in non-small cell lung cancer on cost grounds, prompting renewed calls to update or replace the U.K. Cancer Drugs Fund.